![](https://webarchive.library.unt.edu/eot2008/20090509164942im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090509164942im_/http://www.cancer.gov/images/spacer.gif)
bcr-abl (b3a2)-derived peptide vaccine A peptide vaccine consisting of the bcr-abl b3a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b3a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b3a2 fusion protein.
Fusion genes in CML typically result from the fusion of either BCR exon b2 or BCR exon b3 to ABL exon a2, a 'b3a2' or a 'b2a2' fusion. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090509164942im_/http://www.cancer.gov/images/spacer.gif)
Code name: | ![](https://webarchive.library.unt.edu/eot2008/20090509164942im_/http://www.cancer.gov/images/spacer.gif) | CML-VAX B3 | | ![](https://webarchive.library.unt.edu/eot2008/20090509164942im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090509164942im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509164942im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509164942im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090509164942im_/http://www.cancer.gov/images/spacer.gif) |